An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Atezolizumab
DRUG: Obinutuzumab
DRUG: Tocilizumab
DRUG: Polatuzumab Vedotin
DRUG: 89Zr-Df-IAB22M2C

Sponsor

Hoffmann-La Roche